Cite
HARVARD Citation
Neychev, V. et al. (2015). Mutation-targeted therapy with sunitinib or everolimus in patients with advanced low-grade or intermediate-grade neuroendocrine tumours of the gastrointestinal tract and pancreas with or without cytoreductive surgery: protocol for a phase II clinical trial. BMJ open. 5 (5), p. . [Online].